Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | FAAH | O00519 | 1/20 | 0.31 |
| ▸ | MET | P08581 | 1/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4683303 | 0.91 | CA1 (0.32) | CA1CA2 | |
| SCHEMBL6762060 | 0.91 | CA1 (0.32) | CA1CA2 | |
| SCHEMBL7661158 | 0.84 | CA1 (0.47) | CA1CA2ALDH1A1HPGDLMNA | |
| SCHEMBL6759640 | 0.84 | CA1 (0.47) | CA1CA2ALDH1A1HPGDLMNA | |
| SCHEMBL8027376 | 0.84 | CA1 (0.47) | CA1CA2ALDH1A1HPGDLMNA | |
| SCHEMBL8028041 | 0.84 | CA1 (0.47) | CA1CA2ALDH1A1HPGDLMNA | |
| SCHEMBL7663364 | 0.84 | CA1 (0.47) | CA1CA2ALDH1A1HPGDLMNA | |
| SCHEMBL7669696 | 0.79 | MT-CO2 (0.36) | ALDH1A1HPGD | |
| SCHEMBL6761276 | 0.79 | MT-CO2 (0.36) | ALDH1A1HPGD | |
| SCHEMBL6760790 | 0.76 | CA1 (0.47) | CA1CA2ALDH1A1HPGDLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6723860-B2 | 7a-alkoxy-4H-pyrano[3,2-d]-oxazol-2(3H)-one and process for producing the same | UBE INDUSTRIES, LTD. (JP) | 2004-04-20 | — | — | US | disclosed |
| EP-1207162-B1 | 7a-alkoxy-4H-pyrano-[3,2-d]-oxazol-2(3H)-one and process for producing the same | UBE INDUSTRIES (JP) | 2004-02-25 | — | — | EP | disclosed |
| US-20020072612-A1 | 7a-alkoxy-4H-pyrano [3,2-d] -oxazol-2 (3H) -one and process for producing the same | UBE INDUSTRIES, LTD. (JP) | 2002-06-13 | — | — | US | disclosed |
| EP-1207162-A1 | 7a-alkoxy-4H-pyrano-[3,2-d]-oxazol-2(3H)-one and process for producing the same | Ube Industries, Ltd. (JP) | 2002-05-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020072612-A1 | 7a-alkoxy-4H-pyrano [3,2-d] -oxazol-2 (3H) -one and process for producing the same | ACSL1, ACSL4, ACSL3 | CA1 1373/4885CA2 2720/4885ALDH1A1 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.